GlassScriptPhysician profile
Elias Atri
NPI 1013590959
$1,502.44
in general payments reported to CMS, 2019-2025
14 companies · $628 in 2025
The $628 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.29 · 2022: $95.17 · 2023: $239 · 2024: $474 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $563.13 | 2021-2025 | Lithovue, Ams 700, Accolade Sr |
| Innovation Technologies INC | $172.10 | 2025 | Irrisept |
| Myriad Genetic Laboratories, INC. | $167.59 | 2023 | Prolaris |
| Koelis INC. | $153.61 | 2025 | |
| Pfizer INC. | $97.72 | 2023-2025 | |
| Urogen Pharma, INC. | $95.12 | 2025 | |
| Progenics Pharmaceuticals, INC. | $71.74 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $45.17 | 2024 | |
| Convatec INC. | $33.53 | 2022 | |
| Valencia Technologies Corporation | $26.03 | 2025 | Ecoin Device Kit |
| Sumitomo Pharma America, INC. | $25.27 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $21.13 | 2022 | |
| Foundation Medicine, INC. | $16.32 | 2022 | |
| Philips North America LLC | $13.98 | 2024 | (8584) Uronav |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Atri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.